Delivery Order SPE2DB24D2216-SPE2DB25FGPJM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count supply) with a ceiling value of $51,539.65. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count) with a ceiling value of $2,030.08. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract issued under open competition. The order is scheduled for ultimate completion on July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count) valued at $3,510.76. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by July 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this pharmaceutical supply transaction, which will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count packaging) with a ceiling value of $5,642.09. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by July 29, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count units) with a ceiling value of $11,462.52. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Entresto 24 mg-26 mg tablets (60 count) under a firm fixed-price contract valued at $16,230.90, with completion expected by July 24, 2025. This non-set-aside competitive award represents a child delivery order executed through AmerisourceBergen's broader federal contract vehicle. The contractor, headquartered in Conshohocken, Pennsylvania, holds a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 97 mg-103 mg tablets (60-count units) with a ceiling value of $2,242.17. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 21, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Entresto 49 mg-51 mg tablets (180 count) under a firm fixed price contract valued at $65,700.48, with a completion date of July 24, 2025. This competitively awarded, non-set-aside delivery order represents a continuation of AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The contract is performed at the...
- The Defense Logistics Agency awarded a $7,996.94 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 29, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPJMDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count units) with a ceiling value of $22,448.80. This is a firm fixed price delivery order executed under a non-competitive, non-set-aside procurement. The contractor, headquartered in Conshohocken, Pennsylvania, will perform under this order through the ultimate completion date of August 4, 2025, with the place of performance also located in Conshohocken, PA. This delivery order is issued as a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. That prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. The company maintains a significant federal contract portfolio with DLA and other defense health agencies, regularly delivering brand-name and generic pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains to support military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.4k | 8/1/25 |